Greater Collagen-Induced Platelet Aggregation Following Cyclooxygenase 1 Inhibition Predicts Incident Acute Coronary Syndromes

Clinical and Translational Science

Volumn 8, Issue 1, 2015, Pages 17-22

  Qayyum, Rehan ^a   Becker, Diane M ^a   Yanek, Lisa R ^a   Faraday, Nauder ^a   Vaidya, Dhananjay ^a   Mathias, Rasika ^a   Kral, Brian G ^a   Becker, Lewis C ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Acute coronary syndromes; Aspirin; Collagen; Platelet aggregation

Indexed keywords

ACETYLSALICYLIC ACID; ARACHIDONIC ACID; COLLAGEN; CYCLOOXYGENASE 1; PROSTAGLANDIN SYNTHASE INHIBITOR;

ACUTE CORONARY SYNDROME; ADULT; ARTICLE; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; DIABETES MELLITUS; ENZYME INHIBITION; EX VIVO STUDY; FAMILY HISTORY; FEMALE; FOLLOW UP; FRAMINGHAM RISK SCORE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SEX DIFFERENCE; SMOKING; THROMBOCYTE AGGREGATION; UNSTABLE ANGINA PECTORIS; BLOOD; CONFIDENCE INTERVAL; DRUG EFFECTS; INCIDENCE; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL;

ACUTE CORONARY SYNDROME; ADULT; COLLAGEN; CONFIDENCE INTERVALS; CYCLOOXYGENASE 1; CYCLOOXYGENASE INHIBITORS; FEMALE; HUMANS; INCIDENCE; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PLATELET AGGREGATION; PROPORTIONAL HAZARDS MODELS;

EID: 84922674873     PISSN: 17528054     EISSN: 17528062     Source Type: Journal    
DOI: 10.1111/cts.12195     Document Type: Article

References (44)

1. Arbab-Zadeh A, Nakano M, Virmani R, Fuster V. Acute coronary events. Circulation 2012; 125: 1147-1156.
2. Jackson SP. Arterial thrombosis-insidious, unpredictable and deadly. Nat Med. 2011; 17: 1423-1436.
3. Elwood PC, Renaud S, Beswick AD, O'Brien JR, Sweetnam PM. Platelet aggregation and incident ischaemic heart disease in the Caerphilly cohort. Heart 1998; 80: 578-582.
4. Meade TW, Cooper JA, Miller GJ. Platelet counts and aggregation measures in the incidence of ischaemic heart disease (IHD). Thromb Haemost. 1997; 78: 926-929.
5. Elwood PC, Beswick A, Pickering J, McCarron P, O'Brien JR, Renaud SR, Flower RJ. Platelet tests in the prediction of myocardial infarction and ischaemic stroke: evidence from the Caerphilly Prospective Study. Br J Haematol. 2001; 113: 514-520.
6. Sharp DS, Ben-Shlomo Y, Beswick AD, Andrew ME, Elwood PC. Platelet aggregation in whole blood is a paradoxical predictor of ischaemic stroke: Caerphilly Prospective Study revisited. Platelets 2005; 16: 320-328.
7. Breddin HK, Krzywanek HJ, Althoff P, Kirchmaier CM, Rosak C, Schepping M, Weichert W, Ziemen M, Schoffling K, Uberla K. Spontaneous platelet aggregation and coagulation parameters as risk factors for arterial occlusions in diabetics. Results of the PARD-study. Int Angiol. 1986; 5: 181-195.
8. Breddin HK, Lippold R, Bittner M, Kirchmaier CM, Krzywanek HJ, Michaelis J. Spontaneous platelet aggregation as a predictive risk factor for vascular occlusions in healthy volunteers? Results of the HAPARG Study. Haemostatic parameters as risk factors in healthy volunteers. Atherosclerosis 1999; 144: 211-219.
9. Thaulow E, Erikssen J, Sandvik L, Stormorken H, Cohn PF. Blood platelet count and function are related to total and cardiovascular death in apparently healthy men. Circulation 1991; 84: 613-617.
10. Squizzato A, Keller T, Romualdi E, Middeldorp S. Clopidogrel plus aspirin versus aspirin alone for preventing cardiovascular disease. Cochrane Database Syst Rev. 2011: CD005158.
11. Faraday N, Yanek LR, Mathias R, Herrera-Galeano JE, Vaidya D, Moy TF, Fallin MD, Wilson AF, Bray PF, Becker LC, et al. Heritability of platelet responsiveness to aspirin in activation pathways directly and indirectly related to cyclooxygenase-1. Circulation 2007; 115: 2490-2496.
12. Becker DM, Segal J, Vaidya D, Yanek LR, Herrera-Galeano JE, Bray PF, Moy TF, Becker LC, Faraday N. Sex differences in platelet reactivity and response to low-dose aspirin therapy. JAMA 2006; 295: 1420-1427.
13. Vaidya D, Yanek LR, Moy TF, Pearson TA, Becker LC, Becker DM. Incidence of coronary artery disease in siblings of patients with premature coronary artery disease: 10 years of follow-up. Am J Cardiol. 2007; 100: 1410-1415.
14. Qayyum R, Becker DM, Yanek LR, Moy TF, Becker LC, Faraday N, Vaidya D. Platelet inhibition by aspirin 81 and 325 mg/day in men versus women without clinically apparent cardiovascular disease. Am J Cardiol. 2008; 101: 1359-1363.
15. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972; 18: 499-502.
16. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97: 1837-1847.
17. Faraday N, Yanek LR, Vaidya D, Kral B, Qayyum R, Herrera-Galeano JE, Moy TF, Becker DM, Becker LC. Leukocyte count is associated with increased platelet reactivity and diminished response to aspirin in healthy individuals with a family history of coronary artery disease. Thromb Res. 2009; 124: 311-317.
18. Faraday N, Scharpf RB, Dodd-o JM, Martinez EA, Rosenfeld BA, Dorman T. Leukocytes can enhance platelet-mediated aggregation and thromboxane release via interaction of P-selectin glycoprotein ligand 1 with P-selectin. Anesthesiology 2001; 94: 145-151.
19. Cerletti C, Tamburrelli C, Izzi B, Gianfagna F, deGaetano G. Platelet-leukocyte interactions in thrombosis. Thromb Res. 2012; 129: 263-266.
20. Bochsen L, Johansson PI, Kristensen AT, Daugaard G, Ostrowski SR. The influence of platelets, plasma and red blood cells on functional haemostatic assays. Blood Coagul Fibrinolysis. 2011; 22: 167-175.
21. Santos MT, Valles J, Marcus AJ, Safier LB, Broekman MJ, Islam N, Ullman HL, Eiroa AM, Aznar J. Enhancement of platelet reactivity and modulation of eicosanoid production by intact erythrocytes: a new approach to platelet activation and recruitment. J Clin Invest. 1991; 87: 571-580.
22. Valles J, Santos MT, Aznar J, Marcus AJ, Martinez-Sales V, Portoles M, Broekman MJ, Safier LB. Erythrocytes metabolically enhance collagen-induced platelet responsiveness via increased thromboxane production, adenosine diphosphate release, and recruitment. Blood 1991; 78: 154-162.
23. Stokes J 3rd, Kannel WB, Wolf PA, Cupples LA, D'Agostino RB. The relative importance of selected risk factors for various manifestations of cardiovascular disease among men and women from 35 to 64 years old: 30 years of follow-up in the Framingham Study. Circulation 1987; 75: V65-73.
24. Kral BG, Becker DM, Vaidya D, Yanek LR, Becker LC. Severity of inducible myocardial ischemia predicts incident acute coronary syndromes in asymptomatic individuals with a family history of premature coronary artery disease. J Nucl Cardiol. 2012; 19: 28-36.
25. Williams RL. A note on robust variance estimation for cluster-correlated data. Biometrics 2000; 56: 645-646.
26. Angiolillo DJ, Ueno M, Goto S. Basic principles of platelet biology and clinical implications. Circ J. 2010; 74: 597-607.
27. Badimon L, Vilahur G. Coronary atherothrombotic disease: progress in antiplatelet therapy. Rev Esp Cardiol. 2008; 61: 501-513.
28. Santos MT, Valles J, Aznar J, Perez-Requejo JL. Role of red blood cells in the early stages of platelet activation by collagen. Thromb Haemost. 1986; 56: 376-381.
29. Snoep JD, Gaussem P, Eikenboom JC, Emmerich J, Zwaginga JJ, Holmes CE, Vos HL, deGroot PG, Herrington DM, Bray PF, et al. The minor allele of GP6 T13254C is associated with decreased platelet activation and a reduced risk of recurrent cardiovascular events and mortality: results from the SMILE-Platelets project. J Thromb Haemost. 2010; 8: 2377-2384.
30. Johnson AD, Yanek LR, Chen MH, Faraday N, Larson MG, Tofler G, Lin SJ, Kraja AT, Province MA, Yang Q, et al. Genome-wide meta-analyses identifies seven loci associated with platelet aggregation in response to agonists. Nat Genet. 2010; 42: 608-613.
31. Dumont B, Lasne D, Rothschild C, Bouabdelli M, Ollivier V, Oudin C, Ajzenberg N, Grandchamp B, Jandrot-Perrus M. Absence of collagen-induced platelet activation caused by compound heterozygous GPVI mutations. Blood 2009; 114: 1900-1903.
32. Shaffer JR, Kammerer CM, Dorn J, Ferrell RE, Iacoviello L, Trevisan M, Donahue RP. Polymorphisms in the platelet-specific collagen receptor GP6 are associated with risk of nonfatal myocardial infarction in Caucasians. Nutr Metab Cardiovasc Dis. 2011; 21: 546-552.
33. Kritzik M, Savage B, Nugent DJ, Santoso S, Ruggeri ZM, Kunicki TJ. Nucleotide polymorphisms in the alpha2 gene define multiple alleles that are associated with differences in platelet alpha2 beta1 density. Blood 1998; 92: 2382-2388.
34. Ajzenberg N, Berroeta C, Philip I, Grandchamp B, Ducellier P, Huart V, Verpillat P, Guillin MC, Benessiano J. Association of the -92C/G and 807C/T polymorphisms of the alpha2 subunit gene with human platelets alpha2beta1 receptor density. Arterioscler Thromb Vasc Biol. 2005; 25: 1756-1760.
35. Matarin M, Brown WM, Hardy JA, Rich SS, Singleton AB, Brown RD Jr., Brott TG, Worrall BB, Meschia JF. Association of integrin alpha2 gene variants with ischemic stroke. J Cereb Blood Flow Metab. 2008; 28: 81-89.
36. Cheli Y, Williams SA, Ballotti R, Nugent DJ, Kunicki TJ. Enhanced binding of poly(ADP-ribose)polymerase-1 and Ku80/70 to the ITGA2 promoter via an extended cytosine-adenosine repeat. PLoS One 2010; 5: e8743.
37. Power KA, McRedmond JP, deStefani A, Gallagher WM, Gaora PO. High-throughput proteomics detection of novel splice isoforms in human platelets. PLoS One 2009; 4: e5001.
38. Bynagari-Settipalli YS, Lakhani P, Jin J, Bhavaraju K, Rico MC, Kim S, Woulfe D, Kunapuli SP. Protein kinase C isoform epsilon negatively regulates ADP-induced calcium mobilization and thromboxane generation in platelets. Arterioscler Thromb Vasc Biol. 2012; 32: 1211- 1219.
39. Parodi G, Marcucci R, Valenti R, Gori AM, Migliorini A, Giusti B, Buonamici P, Gensini GF, Abbate R, Antoniucci D, et al. High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing pci. JAMA 2011; 306: 1215-1223.
40. Teixeira R, Monteiro P, Marques G, Pego JM, Lourenco M, Tavares C, Reboredo A, Monteiro S, Goncalves F, Ferreira MJ, et al. Platelet aggregation at discharge: a useful tool in acute coronary syndromes? Rev Port Cardiol. 2012; 31: 545-554.
41. Kojuri J, Mahmoody Y, Zangbar Sabegh B, Jannati M, Mahboodi A, Khalili A. Dose-related effect of aspirin on laboratory-defined platelet aggregation and clinical outcome after coronary stenting. Cardiovasc Ther. 2010; 28: 147-152.
42. Hovens MM, Snoep JD, Eikenboom JC, van derBom JG, Mertens BJ, Huisman MV. Prevalence of persistent platelet reactivity despite use of aspirin: a systematic review. Am Heart J. 2007; 153: 175-181.
43. Aspirin for the prevention of cardiovascular disease: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2009; 150: 396-404.
44. Yee DL, Sun CW, Bergeron AL, Dong JF, Bray PF. Aggregometry detects platelet hyperreactivity in healthy individuals. Blood 2005; 106: 2723-2729.